Andrew P. Mazar spends much of his time researching Cancer research, Urokinase receptor, Angiogenesis, Metastasis and Plasminogen activator. His Cancer research research focuses on Apoptosis and how it connects with KRAS, Lung cancer, Endocrinology and Chemotherapy. His work carried out in the field of Urokinase receptor brings together such families of science as Cell adhesion and Cell biology.
Andrew P. Mazar interconnects Cell and Antimetabolite in the investigation of issues within Angiogenesis. His studies in Metastasis integrate themes in fields like Intraperitoneal injection, Colorectal cancer and Combination therapy. His research integrates issues of Prostate, Cell growth, Growth factor, Biological activity and Primary tumor in his study of Plasminogen activator.
Andrew P. Mazar mostly deals with Urokinase receptor, Cancer research, Molecular biology, Urokinase and Angiogenesis. While the research belongs to areas of Urokinase receptor, Andrew P. Mazar spends his time largely on the problem of Cell biology, intersecting his research to questions surrounding Integrin and Cell adhesion. His Cancer research study combines topics in areas such as Cancer, Metastasis, Tumor progression, In vitro and Immunology.
He has included themes like Transfection, Antibody, Monoclonal antibody, Vitronectin and Binding site in his Molecular biology study. Andrew P. Mazar combines subjects such as Fibrinolysis and Pathology with his study of Urokinase. His study looks at the intersection of Angiogenesis and topics like Biochemistry with Copper metabolism.
His scientific interests lie mostly in Cancer research, Cancer, Urokinase receptor, Kinase and Metastasis. His research in Cancer research intersects with topics in Cell growth, Immunology, Primary tumor, Tumour dormancy and Adenocarcinoma. As part of the same scientific family, Andrew P. Mazar usually focuses on Cancer, concentrating on Apoptosis and intersecting with KRAS and Lung cancer.
His research in Urokinase receptor focuses on subjects like Mesothelial Cell, which are connected to Pathophysiology. His Metastasis research is multidisciplinary, incorporating perspectives in Metastatic breast cancer, Pathology, Cell adhesion, Bone cancer and Extracellular matrix. In his study, Urokinase is inextricably linked to Molecular biology, which falls within the broad field of SOD1.
Cancer research, Metastasis, Cancer, Urokinase receptor and Cell growth are his primary areas of study. His studies deal with areas such as Primary tumor, Organoid and Adenocarcinoma as well as Cancer research. His work deals with themes such as Extracellular matrix, Ovarian cancer, Cell adhesion and Pathology, which intersect with Metastasis.
The concepts of his Cancer study are interwoven with issues in Endocrinology and Angiogenesis. His Urokinase receptor study incorporates themes from Protein kinase B, Protein kinase A, Cancer cell, Liver cancer and Prostate cancer. His study in Cell growth is interdisciplinary in nature, drawing from both SOD1, Molecular biology, KRAS, Lung cancer and Programmed cell death.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Structure of Human Urokinase Plasminogen Activator in Complex with Its Receptor
Qing Huai;Andrew P. Mazar;Alice Kuo;Graham C. Parry.
Structural requirements for the growth factor activity of the amino-terminal domain of urokinase.
Shafaat A. Rabbani;Andrew P. Mazar;Suzanne M. Bernier;Mahmudul Haq.
Journal of Biological Chemistry (1992)
Inhibition of integrin α5β1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice
Oliver Stoeltzing;Wenbiao Liu;Niels Reinmuth;Fan Fan.
International Journal of Cancer (2003)
Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor.
Robert W. Colman;Robin A. Pixley;Syeda Najamunnisa;Wuyi Yan.
Journal of Clinical Investigation (1997)
AN AMINO-TERMINAL FRAGMENT OF UROKINASE ISOLATED FROM A PROSTATE CANCER CELL LINE (PC-3) IS MITOGENIC FOR OSTEOBLAST-LIKE CELLS
Shafast A. Rabbani;Johanne Desjardins;Alexander W. Bell;Denis Banville.
Biochemical and Biophysical Research Communications (1990)
Superoxide dismutase 1 (SOD1) is essential for H2O2-mediated oxidation and inactivation of phosphatases in growth factor signaling
Jose C. Juarez;Mari Manuia;Mark E. Burnett;Oscar Betancourt.
Proceedings of the National Academy of Sciences of the United States of America (2008)
Urokinase-type Plasminogen Activator Receptor (CD87) Is a Ligand for Integrins and Mediates Cell-Cell Interaction
Takehiko Tarui;Andrew P. Mazar;Douglas B. Cines;Yoshikazu Takada.
Journal of Biological Chemistry (2001)
The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis.
Andrew P. Mazar;Jack Henkin;Ronald H. Goldfarb.
The role of the plasminogen activation system in angiogenesis and metastasis.
Shafaat A. Rabbani;Andrew P. Mazar.
Surgical Oncology Clinics of North America (2001)
A non–RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo
Parisa Khalili;Ani Arakelian;Gaoping Chen;Marian L. Plunkett.
Molecular Cancer Therapeutics (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: